JPRN-UMIN000004630招募中2 期
Study of Bevacizumab + Irinotecan + S-1 therapy in metastatic colorectal cancer with KRAS mutant type - Study of Bevacizumab + Irinotecan + S-1 therapy in metastatic colorectal cancer with KRAS mutant type
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) History of severe allergy (2) Active double cancer (3) Severe infectious disease (4) Intestinal tract paralysis or intestinal obstruction (5) Uncontrolled hypertention (6) Sever comorbidity(interstitial lung disease or pulmonary fibrosis, heart failure, renal failure, liver failure, etc) (7) Massive pleural or abdominal effusion (8) Patient with the diarrhea (9) Symptomatic brain metastases (10) Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test (11) Severe mental disorder (12) Systemic administration of corticosteroids (13) Uric protein 2+ (14) Prior radiotherapy for primary and metastases tumors (15) Thrombosis, cerebral infraction, cardiac infraction or pulmonary infraction within 6 months (16) Patients who underwent surgery within 4 weeks (17) Systemic administration of antiplatelet drug (18) Patients with known bleeding disorders or clotting disorder (19) Any other cases who are regarded as inadequate for study enrollmet by investigators
研究者
相似试验
已完成
2 期
Phase II study of TS-1+Irinotecan+Bevacizumab as second-line treatment in patients with metastatic colorectal cancer refractory to fluoronated pyrimidine, oxaliplatin, and cetuximab therapyMetastatic colorectal cancerJPRN-UMIN000010319Japan Clinical Cancer Research Organization70
已完成
1 期
A phaseI/II study of irinotecan with bevacizumab as second line treatment of elderly patients with metastatic colorectal cancer.colorectal cancerJPRN-UMIN000009911Tsuchiura kyodo general hospital25
进行中（未招募）
不适用
Treatment with bevacizumab and irinotecan in patients with recurrent or refractory high grade glioma after conventional treatment. - NDhigh grade gliomaMedDRA version: 9.1Level: LLTClassification code 10065443Term: Malignant gliomaEUCTR2009-012582-64-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
已完成
2 期
Phase II study of bevacizumab and irinotecan plus alternate-day S-1 as second-line therapy in patients with metastatic colorectal cancer.Metastatic colorectal cancer.JPRN-UMIN000008947Epidemiological and Clinical research Information Network (ECRIN)40
撤回
1 期
Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal CancerMetastatic Colorectal CancerNCT03380689Fujian Cancer Hospital